Prestige BioPharma Limited (KRX:950210)

Market Cap	142.67B
Revenue (ttm)	8.66B
Net Income (ttm)	21.79B
Shares Out	12.02M
EPS (ttm)	361.82
PE Ratio	32.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,632
Average Volume	131,196
Open	11,220
Previous Close	11,130
Day's Range	11,140 - 12,130
52-Week Range	8,540 - 20,900
Beta	1.08
RSI	44.16
Earnings Date	May 30, 2025

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 54
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 950210